Health Robotics Reports All-Time Record 105 New Sales in 2Q 2013, Including 67 North American Contracts
BOZEN, Sud-Tirol, Italy, July 15, 2013 /PRNewswire/ --
Health Robotics reported that its 2nd Generation Sterile Compounding Devices continued to dominate the market, accounting for 105 new contracts in 2Q2013, including 23 Robots [5 i.v.STATION ONCO and 18 i.v.STATIONs] and 82 i.v.SOFT workflow software agreements, with a footprint now reaching 450 installations.
North American sales accounted for over 75% of new contracts' revenue with 14 Robots and 53 i.v.SOFT agreements, in great part due to the latest trends to insource Sterile Compounding after the tragic microbiological contamination events in 2012, and the recent FDA inspections of compounding pharmacies in the United States. These record 2Q figures included two new installations under contract to replace some of our competitors' first generation compounding medical devices[1].
Gaspar DeViedma, Health Robotics' Executive Vice President and Board Member, stated: "We are obviously extremely pleased with the best quarterly performance in the company's history and the fact that, as previously forecasted, Health Robotics has already exceeded in the first half of 2013 all of last year total sales results with 137 new contracts YTD. With over 90% 2013's revenues originating from direct sales, I'm now confident that the company has made a successful transition from its prior indirect sales channel business model, and it is no longer dependent on the sales performance of its partner companies around the world."
Although Health Robotics had historically reported new individual hospital sales within a given quarter, it has now become impossible to list all new sales within the period, which are now available at: http://www.health-robotics.com/en/installations/
Mr. DeViedma continued: "With almost 100 i.v.STATION platform 2nd Generation Robots under contract, Health Robotics has now exceeded the number of installations of its first Robot (CytoCare) and is converting customers such as Brigham & Women's Hospital and Peter McCallum Cancer Centre to its new ONCO platform. Going forward, the company will continue to focus on expanding its installed base and direct sales in North America, now reaching almost 200 installations under contract and expected to double over the next 12 months. Overseas, I anticipate that we will continue to adopt the same successful direct sales approach in Western Europe and Australia, dramatically reducing the number of companies and countries with an indirect sales business model."
About Health Robotics:
Founded in 2006 and now reaching 80% total IV Robots market share in the world [including over 90% the Oncology Robots global market], Health Robotics is the undisputed leading supplier of life-critical intravenous medication robots, providing more than 450 hospital installations in 5 continents with the only fully-integrated Robotics-based technology, IV Workflow, and manual compounding software automation solutions. Health Robotics' second generation products [i.v.STATION, i.v.SOFT, and i.v.STATION ONCO] have been found [through scientific and peer-reviewed studies[2],[3]] to greatly contribute to ease hospitals' growing pressures to improve patient safety[2], increase throughput, and contain costs[2]. Through the effective and efficient production of sterile, accurate, tamper-evident and ready-to-administer IVs, Health Robotics' medical devices and integrated workflow solutions help hospitals eliminate life-threatening drug[2] and diluent[2] exchange errors, improve drug potency[3], decrease other medical mistakes and sterility risks, work more efficiently[2], reduce waste and controlled substances' diversion, and diminish the gap between rising patient volume/acuity and scarce nursing, and pharmacy staff. For more information, please visit: http://www.health-robotics.com
--------------------------------------------------
1. Baxter-IntelliFill, Fresenius-MDS, Intelligent Hospital Systems-RIVA, Loccioni
2. Impact of Robotic Antineoplastic Preparation on Safety, Workflow, Costs. Seger, Churchill, Keohane, Belisle, Wong, Sylvester, Chesnick, Burdick, Wien, Cotugno, Bates, and Rothschild. Brigham & Women's Hospital, Massachusetts College of Pharmacy, and Harvard Medical School. Journal of Oncology Practice, Nov. 2012, Volume 8, number 6.
3. Validation of an automated method for compounding monoclonal antibody patient doses: case studies of Avastin®, Remicade®, and Herceptin®. Peters, Capelle, Arvinte, van de Garde. St. Antonius Hospital. mAbs January 2013, Volume 5, Issue 1.
--------------------------------------------------
For additional information, please contact:
Luisa Celeghin
[email protected]
+39-0403-498-468
SOURCE Health Robotics
Share this article